428 related articles for article (PubMed ID: 19483397)
1. Mechanism of immune escape of cancer and its regulation.
Morita R; Hirohashi Y; Torigoe T
Rinsho Ketsueki; 2009 May; 50(5):375-80. PubMed ID: 19483397
[No Abstract] [Full Text] [Related]
2. [HLA-restricted cancer-specific killer T cells].
Harada M; Itoh K
Nihon Rinsho; 2005 Apr; 63 Suppl 4():579-84. PubMed ID: 15861714
[No Abstract] [Full Text] [Related]
3. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
Huang Y; Shah S; Qiao L
Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
[TBL] [Abstract][Full Text] [Related]
4. Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity.
Calderwood SK; Theriault JR; Gong J
Eur J Immunol; 2005 Sep; 35(9):2518-27. PubMed ID: 16144035
[TBL] [Abstract][Full Text] [Related]
5. [Tumor specific antigen and cytotoxic T lymphocytes].
Uenaka A; Nakayama E
Nihon Rinsho; 2005 Apr; 63 Suppl 4():568-73. PubMed ID: 15861712
[No Abstract] [Full Text] [Related]
6. Absence of antitumor natural killer cell-mediated defense in the brain.
Yamasaki T
Surg Neurol; 2004 Mar; 61(3):227-8. PubMed ID: 14984990
[No Abstract] [Full Text] [Related]
7. Tumor escape from the immune response: a major hurdle for successful immunotherapy of cancer?
Chouaib S
Tunis Med; 2005 Dec; 83 Suppl 12():7-10. PubMed ID: 16430055
[No Abstract] [Full Text] [Related]
8. T regulatory cells in cancer: recent advances and therapeutic potential.
Elkord E; Alcantar-Orozco EM; Dovedi SJ; Tran DQ; Hawkins RE; Gilham DE
Expert Opin Biol Ther; 2010 Nov; 10(11):1573-86. PubMed ID: 20955112
[TBL] [Abstract][Full Text] [Related]
9. Tumor microenvironment and immune escape.
Ferrone S; Whiteside TL
Surg Oncol Clin N Am; 2007 Oct; 16(4):755-74, viii. PubMed ID: 18022543
[TBL] [Abstract][Full Text] [Related]
10. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer.
Ferris RL; Whiteside TL; Ferrone S
Clin Cancer Res; 2006 Jul; 12(13):3890-5. PubMed ID: 16818683
[TBL] [Abstract][Full Text] [Related]
11. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
Humphreys RE; Hillman GG; von Hofe E; Xu M
Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
[TBL] [Abstract][Full Text] [Related]
12. Cross-presentation of antigens from apoptotic tumor cells by liver sinusoidal endothelial cells leads to tumor-specific CD8+ T cell tolerance.
Berg M; Wingender G; Djandji D; Hegenbarth S; Momburg F; Hämmerling G; Limmer A; Knolle P
Eur J Immunol; 2006 Nov; 36(11):2960-70. PubMed ID: 17039564
[TBL] [Abstract][Full Text] [Related]
13. Capitalizing on the immunogenicity of dying tumor cells.
Fonseca C; Dranoff G
Clin Cancer Res; 2008 Mar; 14(6):1603-8. PubMed ID: 18347160
[TBL] [Abstract][Full Text] [Related]
14. How tumors escape immune destruction and what we can do about it.
Gilboa E
Cancer Immunol Immunother; 1999 Oct; 48(7):382-5. PubMed ID: 10501851
[TBL] [Abstract][Full Text] [Related]
15. Cell biology. Peptides, scrambled and stitched.
Shastri N
Science; 2006 Sep; 313(5792):1398-9. PubMed ID: 16959995
[No Abstract] [Full Text] [Related]
16. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.
Gajewski TF
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2326s-2330s. PubMed ID: 16609053
[TBL] [Abstract][Full Text] [Related]
17. Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?
Salih HR; Nüssler V
Eur J Med Res; 2001 Aug; 6(8):323-32. PubMed ID: 11549514
[TBL] [Abstract][Full Text] [Related]
18. Modulation of immunological synapse by membrane-bound and soluble ligands.
González PA; Carreño LJ; Figueroa CA; Kalergis AM
Cytokine Growth Factor Rev; 2007; 18(1-2):19-31. PubMed ID: 17344089
[TBL] [Abstract][Full Text] [Related]
19. MHC class I antigens and immune surveillance in transformed cells.
Aptsiauri N; Cabrera T; Garcia-Lora A; Lopez-Nevot MA; Ruiz-Cabello F; Garrido F
Int Rev Cytol; 2007; 256():139-89. PubMed ID: 17241907
[TBL] [Abstract][Full Text] [Related]
20. Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes?
Bangia N; Ferrone S
Immunol Invest; 2006; 35(3-4):485-503. PubMed ID: 16916763
[No Abstract] [Full Text] [Related]
[Next] [New Search]
